home > core services > bioconjugation > cytotoxic antibody drug conjugates (cadcs)
> goodwin biotechnology will design and execute an approach for characterization of your cytotoxic antibody drug conjugate
> goodwin biotechnology will design and execute an approach for characterization of your cytotoxic antibody drug conjugate
Bioconjugation LinksProcess Development
cGMP Manufacturing Cytotoxic Antibody Drug Conjugates (CADCs) MBD-Peptide Technology Other Bioconjugates  Please click on image to enlarge 
Please click on image to enlarge
|
Goodwin Biotechnology will Design and Execute an Approach for Characterization of your Cytotoxic Antibody Drug ConjugateComprehensive analytical characterization is a critical element of developing and manufacturing Cytotoxic Antibody Drug Conjugates (CADCs), and Goodwin Biotechnology will perform assay tech transfer and verification or develop analytical methods to fully characterize your CADC relative to potency, purity, identity, safety, quality, and Drug to Antibody Ratio (DAR). Analytical methods must encompass characterization of the CADC’s Critical Quality Attributes (CQA) and quantification of product-related impurities as well as process-related impurities. This includes determining the percentages of:
For more information, please fill out the form above... thanks! |
For more information on our Cytotoxic Antibody Drug Conjugate (CADCs) services please fill in the form below.
|
